11,100 Shares in Tempus AI, Inc. (NASDAQ:TEM) Purchased by SeaCrest Wealth Management LLC

SeaCrest Wealth Management LLC purchased a new position in Tempus AI, Inc. (NASDAQ:TEM - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,100 shares of the company's stock, valued at approximately $535,000.

A number of other institutional investors also recently bought and sold shares of the stock. ARK Investment Management LLC raised its stake in Tempus AI by 132.1% in the fourth quarter. ARK Investment Management LLC now owns 5,519,644 shares of the company's stock worth $186,343,000 after buying an additional 3,141,487 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. grew its holdings in Tempus AI by 166.0% in the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,239,093 shares of the company's stock worth $109,352,000 after purchasing an additional 2,021,394 shares during the period. Nikko Asset Management Americas Inc. grew its holdings in Tempus AI by 166.0% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,239,093 shares of the company's stock worth $109,352,000 after purchasing an additional 2,021,394 shares during the period. Franklin Resources Inc. grew its holdings in Tempus AI by 240.5% in the fourth quarter. Franklin Resources Inc. now owns 2,762,173 shares of the company's stock worth $93,251,000 after purchasing an additional 1,950,862 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Tempus AI by 86,947.2% in the fourth quarter. JPMorgan Chase & Co. now owns 1,653,896 shares of the company's stock worth $55,836,000 after purchasing an additional 1,651,996 shares during the period. 24.22% of the stock is owned by institutional investors.

Tempus AI Trading Up 5.8%

NASDAQ:TEM opened at $62.07 on Friday. The company's 50 day moving average price is $53.28 and its 200-day moving average price is $52.02. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The stock has a market cap of $10.75 billion and a price-to-earnings ratio of -7.96.

Tempus AI (NASDAQ:TEM - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03. The company had revenue of $255.74 million during the quarter, compared to analysts' expectations of $248.13 million. The business's quarterly revenue was up 75.4% compared to the same quarter last year. On average, equities research analysts forecast that Tempus AI, Inc. will post -6.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO James William Rogers sold 23,030 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $45.97, for a total value of $1,058,689.10. Following the sale, the chief financial officer now owns 164,750 shares in the company, valued at approximately $7,573,557.50. This trade represents a 12.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director David R. Epstein sold 990 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $46.83, for a total transaction of $46,361.70. Following the completion of the sale, the director now owns 26,284 shares in the company, valued at $1,230,879.72. This represents a 3.63% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 139,888 shares of company stock worth $7,938,111. 27.60% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts have weighed in on TEM shares. Morgan Stanley upped their price objective on shares of Tempus AI from $60.00 to $65.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Needham & Company LLC restated a "buy" rating and issued a $70.00 price objective on shares of Tempus AI in a report on Wednesday, May 7th. Piper Sandler upped their price objective on shares of Tempus AI from $55.00 to $70.00 and gave the stock a "neutral" rating in a report on Thursday, May 15th. Wolfe Research cut shares of Tempus AI from a "strong-buy" rating to a "hold" rating in a report on Wednesday, February 26th. Finally, Bank of America upped their price objective on shares of Tempus AI from $48.00 to $68.00 and gave the stock a "neutral" rating in a report on Tuesday, May 20th. Six research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $63.42.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.